Nicotinamide N-methyltransferase and liver diseases

Nicotinamide N-methyltransferase and liver diseases

Cellular metabolism-induced epigenetic regulation is essential for the maintenance of cellular homeostasis. Nicotinamide N-methyltransferase (NNMT) is emerging as a key point of intersection between cellular metabolism and epigenetic regulation and has a central role in various physiological and pat...

Bibliográfalaš dieđut
Váldodahkkit:	Guangyu Liang, Ying Li, Yan Lin, Xiao Yang, Jiankun Yang, Shaobo Hu, Anding Liu
Materiálatiipa:	Artihkal
Giella:	English
Almmustuhtton:	KeAi Communications Co., Ltd. 2023-09-01
Ráidu:	Genes and Diseases
Fáttát:	Epigenetics Liver diseases Metabolism Nicotinamide N-methyltransferase Non-alcoholic fatty liver disease
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2352304222000952

Geahča maid

Novel Inhibitors of Nicotinamide-<i>N</i>-Methyltransferase for the Treatment of Metabolic Disorders
Dahkki: Aimo Kannt, et al.
Almmustuhtton: (2021-02-01)

Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome
Dahkki: Wei-Dong Sun, et al.
Almmustuhtton: (2024-06-01)

Time-restricted feeding ameliorates non-alcoholic fatty liver disease through modulating hepatic nicotinamide metabolism via gut microbiota remodeling
Dahkki: Ruijia Feng, et al.
Almmustuhtton: (2024-12-01)

Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions
Dahkki: Jing-Jing Li, et al.
Almmustuhtton: (2024-06-01)

Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice
Dahkki: Andrea L. Dimet-Wiley, et al.
Almmustuhtton: (2024-07-01)

A Case Study of Dysfunctional Nicotinamide Metabolism in a 20-Year-Old Male
Dahkki: Karen L. DeBalsi, et al.
Almmustuhtton: (2023-03-01)

Nicotinamide N-Methyltransferase in Head and Neck Tumors: A Comprehensive Review
Dahkki: Lucrezia Togni, et al.
Almmustuhtton: (2021-10-01)

Nicotinamide riboside exerts protective effect against aging-induced NAFLD-like hepatic dysfunction in mice
Dahkki: Xue Han, et al.
Almmustuhtton: (2019-08-01)

Elucidating the role of nicotinamide N-methyltransferase-p53 axis in the progression of chronic kidney disease
Dahkki: Xin Zhen, et al.
Almmustuhtton: (2023-11-01)

Circular RNA as An Epigenetic Regulator in Chronic Liver Diseases
Dahkki: Xianhui Zeng, et al.
Almmustuhtton: (2021-07-01)

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Dahkki: Eileen L. Yoon, et al.
Almmustuhtton: (2024-01-01)

Overlapping group between non‐alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research
Dahkki: Yu‐Ming Cheng, et al.
Almmustuhtton: (2024-10-01)

Nicotinamide <i>N</i>-Methyltransferase as Promising Tool for Management of Gastrointestinal Neoplasms
Dahkki: Valentina Pozzi, et al.
Almmustuhtton: (2022-08-01)

Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease
Dahkki: Akash Roy, et al.
Almmustuhtton: (2024-09-01)

The Utility of Nicotinamide N-Methyltransferase as a Potential Biomarker to Predict the Oncological Outcomes for Urological Cancers: An Update
Dahkki: Roberto Campagna, et al.
Almmustuhtton: (2021-08-01)

Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
Dahkki: Byeong Geun Song, et al.
Almmustuhtton: (2023-09-01)

Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease
Dahkki: A. Lum Han, et al.
Almmustuhtton: (2022-07-01)

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review
Dahkki: Chavdar S. Pavlov, et al.
Almmustuhtton: (2024-05-01)

Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality
Dahkki: Yuri Ogasawara, et al.
Almmustuhtton: (2023-06-01)

Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
Dahkki: Ji-Qiao Zhu, et al.
Almmustuhtton: (2024-04-01)

Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
Dahkki: Tae Seop Lim, et al.
Almmustuhtton: (2023-07-01)

Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
Dahkki: Divyavani Gowda, et al.
Almmustuhtton: (2023-11-01)

A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
Dahkki: Jiang YJ, et al.
Almmustuhtton: (2024-04-01)

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
Dahkki: Cheng-Wei Yu, et al.
Almmustuhtton: (2023-12-01)

Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease
Dahkki: Kun-Lin Cheng, et al.
Almmustuhtton: (2024-01-01)

Non-alcoholic fatty liver disease: current aspects of diagnosis in real clinical practice
Dahkki: Dmitry I. Trukhan
Almmustuhtton: (2021-04-01)

Steatosis, inflammation, fibroprogression, and cirrhosis in remnant liver post‐liver donation
Dahkki: Jeby Jacob, et al.
Almmustuhtton: (2024-08-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Dahkki: Gi-Ae Kim, et al.
Almmustuhtton: (2023-10-01)

Research Progress in the Correlation of Non-alcoholic Fatty Liver Disease and Metabolic-associated Fatty Liver Disease with Cardiovascular Diseases in China and Abroad
Dahkki: NI Xuetong, WANG Ruoxi, ZHANG Jing, YANG Xinghua
Almmustuhtton: (2024-06-01)

Non-Alcoholic Fatty Liver Disease and COVID-19–Two Pandemics Hitting at the Same Time
Dahkki: Luka Vranić, et al.
Almmustuhtton: (2021-10-01)

Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
Dahkki: Yohwan Lim, et al.
Almmustuhtton: (2023-06-01)

Nonalcoholic fatty liver disease burden – Switzerland 2018–2030
Dahkki: Nicolas Goossens, et al.
Almmustuhtton: (2019-12-01)

Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children
Dahkki: Cynthia A. Moylan, et al.
Almmustuhtton: (2022-11-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
Dahkki: Gong Feng, et al.
Almmustuhtton: (2025-03-01)

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
Dahkki: Mubin Ozercan, et al.
Almmustuhtton: (2025-01-01)

Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight
Dahkki: Anqi Li, et al.
Almmustuhtton: (2024-06-01)

Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
Dahkki: Jin Imai, et al.
Almmustuhtton: (2024-06-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
Dahkki: Jessica M. Rubino, et al.
Almmustuhtton: (2025-01-01)

Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action
Dahkki: Vanessa D. de Mello, et al.
Almmustuhtton: (2017-04-01)

Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review
Dahkki: Tatiana Y. Demidova, et al.
Almmustuhtton: (2023-11-01)